ReviewCureus2026

The Transition From Sunitinib Monotherapy to Modern First-Line Tyrosine Kinase Inhibitor (TKI)-Containing Regimens in Metastatic Clear-Cell Renal Cell Carcinoma.

Sravani Manda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.